Regeneron Pharmaceuticals Inc. (REGN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Regeneron Pharmaceuticals Inc. (REGN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How REGN Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $14.34B | 44% | 24.9% | $4.50B | $4.33B | 9.4% |
| FY 2024 | $14.20B | 44% | 28.1% | $4.41B | $3.78B | 10.9% |
| FY 2023 | $13.12B | 44% | 30.9% | $3.95B | $4.00B | 11.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring REGN)
- ✓Live walkthrough of REGN's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
REGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on REGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for REGN. Explore sector supply chains on /butterfly.
REGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Regeneron Pharmaceuticals Inc. (REGN)?
In FY 2025 (10-K), REGN converted $14.3B of revenue into a 44% gross margin, 24.9% operating margin, and $4.3B in free cash flow (30.2% FCF margin).